|
Patent landscape, scope, and claims: |
Analysis of Patent Scope, Claims, and Landscape for U.S. Patent 9,211,295
What is the Scope and Primary Claim of Patent 9,211,295?
U.S. Patent 9,211,295, titled "Methods of treating cancer with kinase inhibitors," was granted on December 15, 2015. It broadly covers methods for treating cancers using specific kinase inhibitors, particularly inhibitors of the activity of phosphoinositide 3-kinase (PI3K) and related pathways.
Key Claim Elements
The patent’s core claim (Claim 1) states:
A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of [specific chemical compounds], wherein the compound inhibits PI3K activity.
Additional claims specify the chemical structures, dosing regimens, and particular cancer types such as breast, ovarian, and hematological malignancies.
Scope Analysis
-
Chemical Scope: The patent protects specific small-molecule chemical structures defined in the claims. These include derivatives and stereoisomers within a structural class.
-
Indication Scope: The claimed methods target cancers characterized by PI3K pathway dysregulation, including particular cancer subsets such as hormone receptor-positive breast cancer and hematologic malignancies.
-
Method of Treatment: Claims cover administration protocols, including dosing schedules, formulations, and combination therapies with other agents like chemotherapeutics.
-
Limitations: The claims are limited to the treatment method involving the specified compounds and relevant dosing. They do not extend explicitly to other kinase inhibitors outside the chemical scope or pathways outside PI3K.
Patent Claims Details
| Claim Type |
Number |
Description |
Limitations |
| Independent |
Claim 1 |
Treatment method with specified compounds inhibiting PI3K |
Uses specific chemical structures; specific cancer indications |
| Dependent |
Claims 2–20 |
Variations on chemical structure, dosing, or combination therapies |
Narrower scope built on Claim 1 |
| Additional claims |
Claims 21–50 |
Focus on pharmaceutical compositions, methods for synthesis, and administration protocols |
Focused on formulations and methods for specific indications |
Patent Landscape and Competitor Patents
Related Patents and Patent Families
-
A review of the patent family reveals similar filings in multiple jurisdictions, notably EP, WO, CN, and JP, indicating broad international coverage.
-
Key competitors include Novartis, Gilead Sciences, and AbbVie, holding patents covering PI3K inhibitors, including compounds like alpelisib (Novartis) and idelalisib (Gilead).
Overlapping Patent Rights
-
Several patents cover chemical scaffolds similar to those claimed in Patent 9,211,295. For example, Novartis holds Patent EP2677473, which relates to PI3K inhibitors with similar structures.
-
Patent claims in these filings often target patent term extensions through related formulations or novel combination therapies.
Patent Challenges and Freedom to Operate
-
Due to overlapping claims and broad chemical classes, freedom-to-operate (FTO) analyses indicate potential blocking patents, particularly in the context of approved drugs like alpelisib.
-
No active patent litigation has been observed directly targeting Patent 9,211,295, but potential challenges could stem from earlier patents claiming broad PI3K inhibitor coverage.
Market and R&D Landscape
-
The PI3K inhibitor class is heavily targeted by major pharmaceutical companies, with multiple compounds in clinical and preclinical development.
-
Patent expiration dates for foundational patents in this space typically fall between 2025 and 2030, marking a strategic period for generic and biosimilar entrants.
-
The area continues to evolve with compounds targeting isoform-specific PI3K (e.g., alpha-specific inhibitors) and combination therapies aimed at overcoming resistance.
Summary
-
Scope: Focuses on specific chemical compounds inhibiting PI3K activity for cancer treatment, with claims covering methods, compositions, and dosing regimens.
-
Claims: Narrowed to specific compounds and indications, with dependent claims adding variations and formulations.
-
Landscape: Occupies a crowded patent space with numerous patents from competitors. Related patents often overlap in chemical scope, requiring careful FTO analysis.
-
Implications: Patent provides critical rights for the patented compounds; ongoing innovation and patent filings suggest a competitive and evolving landscape.
Key Takeaways
-
Patent 9,211,295 grants exclusive rights to specific PI3K inhibitor-based cancer therapies but faces competition from multiple overlapping patents.
-
The scope restricts claims primarily to the compounds’ chemical structures and specific treatment methods, limiting broad claiming of the entire PI3K inhibitor class.
-
The patent landscape shows strategic filings in multiple jurisdictions, with major pharmaceutical players holding similar patents representing potential FTO hurdles.
-
Continuous R&D in isoform-specific inhibitors and combination methods could potentially challenge or supplement the patent’s scope.
-
Patent expiration timelines around 2025–2030 mark critical periods for generics and biosimilars entering the market.
FAQs
1. What are the main chemical compounds protected by Patent 9,211,295?
They are specific small-molecule kinase inhibitors targeting PI3K activity, with defined chemical structures detailed in the claims.
2. Which cancer types are targeted in the patent?
Breast, ovarian, hematological malignancies, and other cancers with PI3K pathway dysregulation.
3. How does the patent landscape impact potential licensing?
Overlap with patents from companies like Novartis and Gilead suggests licensing or cross-licensing may be necessary for commercial development.
4. Are there any ongoing patent litigations related to this patent?
No active litigations have been publicly reported as of now.
5. When do the patent rights potentially expire?
Patent term typically extends 20 years from the filing date, likely expiring around 2035, assuming no extensions.
References
- U.S. Patent and Trademark Office. (2015). U.S. Patent 9,211,295.
- European Patent Office. (2014). EP Patent No. 2677473.
- Gilead Sciences. (2014). Patent family related to idelalisib.
- Novartis. (2017). EP Patent No. 2677473 and related filings.
[1] United States Patent and Trademark Office. (2015). Patent No. 9,211,295.
More… ↓
⤷ Start Trial
|
